Abstract
Background and objectives
Cerebral small vessel disease (CSVD) is associated to cognitive decline and dementia. Neuroimaging changes of CSVD are highly prevalent above 80 years. Only few studies report on incidence of CSVD in high age. We have investigated the incidence and prevalence of magnetic resonance imaging (MRI) markers of CSVD and risk factors in the general older population.
Methods
As part of the general population Good Aging in Skåne cohort study (GÅS), 241 persons (mean age 76.3 years) underwent two brain MRI, 3-T scanner with a mean interval of 5.9 years. The incidence of white matter hyperintensities (WMH), lacunar infarction, cerebral atrophies and cerebral microbleeds (CMB) were calculated and the relationship to risk factors analysed by a multivariate regression analysis. Medial temporal lobe atrophy (MTA) was graded according to Scheltens’18 scale and CMB were defined as having > 1 small (0.2–0.5 cm) hypointense lesion.
Results
The 6-year incidence of CMB, WMH and MTA were, 19%, 17% and 13% respectively, corresponding to 170/1,000 py., 172/1,000 py., and respectively 167/1,000 py. The incidence of CSVD according to the modified STRIVE score was 33%, 169/1,000 py and the prevalence at baseline was 73%. Moderate to high intake of alcohol was related to increased incidence of MTA and higher STRIVE score. Exposure to smoking was related to higher incidence of CMB and higher STRIVE score, adjusted for other known risk factors.
Conclusion
CSVD is highly prevalent in the general older population and the 6-year incidence of WMH, CMB and MTA ranges from 13 to 19 percent. The modifiable lifestyle factors: smoking, and moderate alcohol intake are related to incident CSVD.
Similar content being viewed by others
![](https://media.springernature.com/w215h120/springer-static/image/art%3A10.1134%2FS0362119721080119/MediaObjects/10747_2022_8385_Fig1_HTML.gif)
Avoid common mistakes on your manuscript.
Introduction
Cerebral small vessel disease (CSVD) involves small cerebral vessels that perfuse white matter tracts, basal ganglia, thalamus, and pons. The condition increases with age, affecting about 5% of people aged 50 years, to almost 100% of people older than 90 years [1]. CSVD can be asymptomatic. Clinical manifestations as cognitive decline, dementia, stroke, depressive mood and gait disturbances have been associated to CSVD, although the consequences are unknown and cognitive healthy persons can show these changes why the clinical relevance has been highlighted [2]. The neuroimaging markers of CSVD include small infarctions, white matter hyperintensities (WMH), lacunar infarctions, cerebral microbleeds (CMB), enlarged perivascular spaces, and cerebral atrophy [3, 4]. The interest of CSVD has increased globally since the condition is one of the single most common cause of stroke injury and risk factor for cognitive impairment [5]. The most common pathologies are cerebral amyloid angiopathy and hypertensive related small vessel disease. Vascular risk factors are associated to CSVD such as hypertension, hypercholesterolemia and diabetes, but less have been studied on modifiable lifestyle factors like smoking, alcohol and physical activity [6].. Furthermore, results on alcohol intake are contradictory [6].
Prevalence of CSVD increases with age, especially WMH and CMB. No sex differences are noted (1). WMH progression predicted incident all-cause dementia during 14-year follow-up [7]. A similar study, the Rotterdam Scan study, reported progression of periventricular white matter lesions among 27% and incident CMB among 10% with repeated MRI of older subjects during a 3.4-year follow-up (mean age 71 yrs.) [8, 9]. The most common clinical manifestations are with lacunar stroke and cognitive impairment but in the early stages of CSVD there are no symptoms, only imaging changes. Few studies describe incidence of imaging CSVD including WMH, CMB, lacunar infarction and atrophy. The underlying aetiology of CMB depends on spatial distribution with deep/infratentorial CMB more related to hypertensive vasculopathy. This spatial distribution was not specifically analysed in this study.
We investigated the prevalence and six-year incidence of neuroimaging markers of CSVD in a large population-based sample of older subjects. Furthermore, we studied the relationship between incident lesions and modifiable risk factors.
Methods
The study is based on the ongoing population-based cohort study “Good Aging in Skåne” (GÅS), part of the “Swedish National study on Aging and Care” (SNAC) [10, 11]., investigating age-related changes on MRI of the brain in an observational cohort design. We have previously reported prevalence of CSVD at the baseline examination [12].. Of the 407 eligible persons from baseline, 241 (59%) participated in a 6-year follow-up during 2022 to 2023. 34 subjects were deceased, 10 subjects were unable to reach, 6 subjects had pacemaker, 5 subjects had dementia and 111 declined to participate. The survey included physical and medical examination by a physician, medical history and information from medical records, anthropometrics, and lifestyle factors from a self-reported questionnaire in an outpatient setting. Cystatin C and creatinine were analysed and estimated glomerular filtration (eGFR) was calculated from the well-established chronic kidney disease epidemiology collaboration (CKD-EPI) formula adjusted for age and sex [13].CKD is defined as having an eGFR < 60 ml/min/1.73 m2. Coronary artery disease included heart failure, angina pectoris, atrial fibrillation and presence of cardiac vascular implants or grafts. Stroke/TIA included nontraumatic intracranial haemorrhage, cerebral infarction, and transient ischemic episodes. All diagnoses were derived from the medical examination and medical records and the National Inpatient and Outpatient Register and coded according to the International Classification of Diseases, ICD-9, and ICD-10 to avoid recall bias.
Smoking habits were categorized into three groups, regular/occasional smoking, former smokers, and nonsmokers. Physical activity was divided into two categories, low to medium activity referring to a sedentary lifestyle or light activity for 2–4 h weekly, and high activity with gardening, running or other strenuous activities for > 3 h weekly. Alcohol intake the past year was categorized into three groups, several times a week, less than once a week and teetotaller. Cognitive function was assessed by the Mini Mental State Examination (MMSE) were < 24 score indicate impaired cognition, 25–27 intermediate cognition and scores between 28–30 normal cognition.
MRI examination with a three Tesla MRI (General Electric, discovery MR 750w) included axial T2‐weighted fluid‐attenuated inversion recovery (T2 FLAIR), axial diffusion‐weighted images (DWI), and axial susceptibility‐weighted angiography (SWAN). SWAN sequences were acquired at two settings: 3‐mm‐thick SWAN images and 5‐mm‐thick phase images in order to differentiate blood from calcifications. Furthermore, sagittal T1‐weighted 0.9‐mm isotropic 3D fast spoiled gradient echo (3D‐FSPGR) images were performed and reconstructed in the axial and coronal planes. All MR images were assessed by an experienced neuroradiologist, by KAK (one of the authors) at baseline and by ES at the six-year follow-up, blinded for clinical information. White matter hyperintensities (WMH) changes were assessed by FLAIR sequences. Presence of WMH was graded by the Fazekas scale, where a score of > 2 was considered pathological for WMH [14].. Lacunar infarctions were defined as having > 1 ischemic infarction (< 1.0 cm) in the deep white matter, the basal ganglia and pons [15].. Cerebral microbleeds (CMB) were defined as having > 1 small (0.2–0.5 cm) hypointense lesion [15] using the SWAN sequence. Medial temporal atrophy (MTA) was graded according to Scheltens’18 scale, parietal atrophy graded according to Koedam scale [16]., global cortical atrophy (GCA) assessed according to the Pasquier scale [17]and specific types of atrophy, including frontal cortical, temporal cortical and frontotemporal atrophy were assessed. A modified STRIVE variable from Standards for reporting vascular changes on neuroimaging (STRIVE and STRIVE-2) presented by Wardlaw [3, 18] was defined as presence of at least one of the following: Fazekas scale ≥ 2, ≥ 1 lacunar infarct, ≥ 1 CMB, cortical atrophy, and specific atrophy. The same MRI protocol was used at both examinations.
MRI diagnoses of CMB have proven to be reproducible with good to very good intra‐ and inter-rater agreement (intra-rater kappa = 0.85 [95% confidence interval (CI) 0.77‐0.93]; interrater kappa = 0.68 [95% CI: 0.58‐0.78]) in previous studies [19]..
Incidence and prevalence of CSVD were calculated and a logistic multivariate regression model for analyses of association between incident cases of CSVD and established risk factors such as age, lifestyle factors, coronary and cerebrovascular diseases, diabetes, hyperlipidaemia, and hypertension. Chi square statistics were used for analyses of differences between participants and non-participants at follow-up. All statistical analyses were performed using the software IBM SPSS version 27. The statistical significance level was set at 5%. The STROBE checklist for cohort studies was used.
Results
The mean age of the study sample at baseline was 76.3 years and mean follow-up time was 5.9 years. A higher proportion of the participants at follow-up had high physical activity, were non-smokers and reported moderate to high alcohol intake compared to non-participants, see Table 1.
Prevalence of the MRI findings at the baseline survey and their 6-year incidence are presented in Table 2. CMB, WMH and MTA had the highest 6-year incidence, 19%, 17% and 13% respectively, corresponding to 170/1000 py., 172/1000 py., and respectively 167/1000 py, see Table 2. The incidence of CSVD according to the modified STRIVE was 33%, 169/1000 py., and the prevalence of STRIVE was 73% at baseline. Higher numerically incidence was noted for the following CSVD lesions: WMH, CMB, GCA, MTA, lacunar infarction and specific atrophy, among older participants at age 76–87 yr., compared to the 72–75 yr. group, with a mean difference of incidence ranging from 8/1000 py. to 17/1000 py., as presented in Table 2.
Sixteen out of the 241 subjects (7%) had regression of one or more of the CSVD lesions: reduction in number of lacunar infarctions in 11 subjects, precuneus atrophy in 3 subjects, Koedam parietal atrophy, specific atrophy, and number of CMB in 2 subjects each, and GCA, WMH and MTA in 1 subject.
Table 3 presents the relationship and odds ratios between life-style factors and the incidence of CSVD lesions 6 years later. Moderate to high intake of alcohol was related to increased incidence of MTA and higher STRIVE score, while exposure to smoking was related to a higher incidence of CMB and higher STRIVE score, adjusted for other known risk factors.
Discussion
Incidence of CSVD is common and a third of an older general population in this study develop CSVD during a 6-year follow-up according to a modified STRIVE score and 13–19% develop either CMB, MTA or WMH. The incidence of CSVD is related to smoking and moderate to high alcohol intake.
Most previous studies on CSVD are cross-sectional, include somewhat younger populations up to 70 years, and presented variation in incidence and prevalence which could depend on difference in MRI techniques used and definitions of imaging findings. The Rotterdam Scan study reported an overall 16% incidence of CMB in 70–79-year-old participants, which is like our findings [9, 20]. Also, the prevalence of CMB at baseline examinations was similar between these two studies: 32% compared to 28% in our study. The incidence of lacunar infarction in the Three city-Dijon study with 4-year follow-up was 10%, which is similar to 9% in this study [21]. Previous studies have highlighted the need for age stratification instead of incorporating age as an independent variable since CSVD is not consistent among age groups [22].The burden of CSVD increases with age and the annual incidence noted in this study is about 2% in the general older population and similar or higher than many of other prevalent chronic disorders among older subjects. For example, the annual incidence of hip fracture is 1.% in women and 0.7% in men above 70 years [23] and the incidence of stroke between 0.7 and 1.0% for those aged 65–74 in US [24]. This study report that the high incidence of CSVD remains above 80 year of age.
It is important to identify possible modifiable risk factors of CSVD to prevent the condition. A recent meta-analysis identified hypertension, diabetes, smoking and hyperlipidaemia as risk factors for CSVD (6). Alcohol consumption is a significant risk factor for stroke [25], but results on association to CSVD are contradictory. High intake of alcohol is related to cerebral atrophy and involvement of the insular cortex, part of the temporal lobe and low to moderate intake of alcohol is associated with a reduced risk of ischemic stroke [26]. We noted an increased risk for moderate alcohol consumption in relation to MTA. The effect of smoking was studied previously in pooled analyses indicating an effect on both WMH and lacunar infarction and in accordance with the findings in the present study [6].
The findings in this study indicate that the longstanding effect of exposure to the modifiable lifestyle factors smoking and alcohol remains at high age and could be detected as increased incidence of CSVD above 75 years of age.
We have previously reported on the cross-sectional findings of CSVD and at follow-up in this study the participants had higher alcohol intake and higher physical activity but less hypertension than the non-participants [12].A selection bias with more healthier subjects cannot be ruled out and the observed incidence might underestimate true incidence of CSVD. Furthermore, the high age of the study population ranging from 70 to 87 years at inclusion also cause additional attrition bias of the detrimental effects of risk-factors like high exposure to smoking and alcohol since those subjects to a higher degree are deceased. The improved treatment the past decades of several cardiovascular risk factors like hypertension and diabetes, RAS inhibitors that reduce progression of chronic kidney disease and cardiovascular events and cessation of smoking will most likely slow down the progression of CSVD in the very old. Future studies will evaluate these effects on newer birth cohorts with changed life-time exposure of risk-factors on CSVD.
The findings from the MMSE describing the general cognitive level among the participants indicates that the vast majority had a high functioning level (> 27 MMSE score) despite the high prevalence of CSVD related MRI markers. The relationship between imaging findings and change in cognitive function, especially executive functions also need to be further explored. There are few treatments for established CSVD, and further studies are needed to understand the pathogenesis and factors influencing progression [27]. The absence of autopsy is a limitation since it could have reduced possible misinterpretations of the MR related CVSD lesions and future studies would benefit with information on ApoE status and family history of cognitive decline or PD. Lack of analyses of superficial siderosis as a MR marker of cerebral amyloid angiopathy is another limitation.
In conclusion, CSVD is highly prevalent in the general older population above 80 year of age and the 6-year incidence of WMH, CMB and MTA ranges from 13–19%. The modifiable life-style factors smoking, and moderate alcohol intake are related to incident CSVD.
References
Cannistraro RJ, Badi M, Eidelman BH, Dickson DW, Middlebrooks EH, Meschia JF (2019) CNS small vessel disease: a clinical review. Neurology 11:1146–1156. https://doi.org/10.1212/WNL.0000000000007654
Pasi M, Cordonnier C (2020) Clinical relevance of cerebral small vessel diseases. Stroke. https://doi.org/10.1161/STROKEAHA.119.024148
Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O’Brien JT, Barkhof F, Benavente OR et al (2013) STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 12:822–838. https://doi.org/10.1016/S1474-4422(13)70124-8
Singh A, Bonnell G, De Prey J, Buchwald N, Eskander K, Kincaid K, Wilson C (2023) Small-vessel disease in the brain. Am Heart J Plus Cardiol Res Pract 27:100277. https://doi.org/10.1016/j.ahjo.2023.100277
Kalaria RN, Akinyemi RO, Paddick SM, Ihara M (2024) Current perspectives on prevention of vascular cognitive impairment and promotion of vascular brain health. Expert Rev Neurother 24:25–44. https://doi.org/10.1080/14737175.2023.2273393
Wang Z, Chen Q, Chen J, Yang N, Zheng K (2021) Risk factors of cerebral small vessel disease: A systematic review and meta-analysis. Medicine (Baltimore) 23:10028229. https://doi.org/10.1097/MD.0000000000028229
Jacob MA, Cai M, van de Donk V, Bergkamp M, Marques J, Norris DG, Kessels RPC, Claassen JAHR, Duering M, Tuladhar AM, Leeuw FE (2023) Cerebral small vessel disease progression and the risk of dementia: a 14-year follow-up study. Am J Psychiatry 180(7):508–518. https://doi.org/10.1176/appi.ajp.20220380
van Dijk EJ, Prins ND, Vrooman HA, Hofman A, Koudstaal PJ, Breteler MM (2008) Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam scan study. Stroke 39:2712–2719. https://doi.org/10.1161/STROKEAHA.107.513176
Poels MM, Ikram MA, van der Lugt A, Hofman A, Krestin GP, Breteler MM, Vernooij MW (2011) Incidence of cerebral microbleeds in the general population: the Rotterdam scan study. Stroke 42(3):656–661. https://doi.org/10.1161/STROKEAHA.110.607184
Ekström H, Elmståhl S (2006) Pain and fractures are independently related to lower walking speed and grip strength: results from the population study “Good Ageing in Skåne.” Acta Orthop 6:902–911
Lagergren M, Fratiglioni L, Hallberg IR, Berglund J, Elmståhl S, Hagberg B, Holst G, Rennemark M, Sjolund BM, Thorslund M et al (2004) A longitudinal study integrating population, care and social services data. The Swedish National study on Aging and Care (SNAC). Aging Clin Exp Res 16:158–168
Elmståhl S, Ellstrom K, Siennicki-Lantz A, Abul-Kasim K (2019) Association between cerebral microbleeds and hypertension in the Swedish general population “Good Aging in Skåne” study. J Clin Hypertens 21(8):1099–1107
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612
Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjogren M, Wallin A, Ader H, Leys D, Pantoni L et al (2001) A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 32(6):1318–1322
Offenbacher H, Fazekas F, Schmidt R, Koch M, Fazekas G, Kapeller P (1996) MR of cerebral abnormalities concomitant with primary intracerebral hematomas. AJNR Am J Neuroradiol 17(3):573–578
Koedam EL, Lehmann M, van der Flier WM, Scheltens P, Pijnenburg YA, Fox N, Barkhof F, Wattjes MP (2011) Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol 21(12):2618–2625
Pasquier F, Leys D, Weerts JG, Mounier-Vehier F, Barkhof F, Scheltens P (1996) Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol 36(5):268–272. https://doi.org/10.1159/000117270
Duering M, Biessels GJ, Brodtmann A, Chen C, Cordonnier C, de Leeuw FE, Debette S, Frayne R, Jouvent E, Rost NS et al (2023) Neuroimaging standards for research into small vessel disease-advances since 2013. Lancet Neurol 22(7):602–618. https://doi.org/10.1016/S1474-4422(23)00131-X
Gregoire SM, Chaudhary UJ, Brown MM, Yousry TA, Kallis C, Jäger HR, Werring DJ (2009) The microbleed anatomical rating scale (MARS): reliability of a tool to map brain microbleeds. Neurology 73(21):1759–1766. https://doi.org/10.1212/WNL.0b013e3181c34a7d
Poels MM, Vernooij MW, Ikram MA, Hofman A, Krestin GP, van der Lugt A, Breteler MM (2010) Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam scan study. Stroke 41(10 Suppl):S103–S106. https://doi.org/10.1161/STROKEAHA.110.595181
Satizabal CL, Zhu YC, Mazoyer B, Dufouil C, Tzourio C (2012) Circulating IL-6 and CRP are associated with MRI findings in the elder: the 3C-Dijon Study. Neurology 78(10):720–727. https://doi.org/10.1212/WNL.0b013e318248e50f
Mu R, Qin X, Guo Z, Meng Z, Liu F, Zhuang Z, Zheng W, Li X, Yang P, Feng Y, Jiang Y, Zhu X (2022) Prevalence and consequences of cerebral small vessel diseases: a cross-sectional study based on community people plotted against 5-yar age strata. Neuropsychiatr Dis Treat 18:499–512
Kannus P, Parkkari J, Sievänen H, Heinonen A, Vuori I, Järvinen M (1996) Epidemiology of hip fractures. Bone 18(1 Suppl):57S-63S. https://doi.org/10.1016/8756-3282(95)00381-9
Roger VL, Go AS, Lloyd-Jones DM et al (2011) Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation 123:e18–e209. https://doi.org/10.1161/CIR.0b013e3182009701
Jeong SM, Lee HR, Han K, Jeon KH, Kim D, Yoo JE, Cho MH, Chun S, Lee SP, Nam KW, Shin DW (2022) Association of change in alcohol consumption with risk of ischemic stroke. Stroke 53(8):2488–2496. https://doi.org/10.1161/STROKEAHA.121.037590
Chattopadhyay S, Srivastava M, Srivastava AS, Srivastava A (2011) Structural changes in the insular cortex in alcohol dependence: a cross sectional study. Iran J Psychiatry 6(4):133–137
Markus HS, de Leeuw FE (2023) Cerebral small vessel disease: Recent advances and future directions. Int J Stroke 18(1):4–14. https://doi.org/10.1177/17474930221144911
Funding
Open access funding provided by Lund University. The project Good Aging in Skåne, part of the Swedish National Study on Aging and Care (www.snac.org) was supported by the Swedish Ministry of Health and Social Affairs, the County of Region Skåne and the Swedish Research Council under Grant No. 2017-01613; 521-2013-8604, 2021-00178 and 2021-01437. This research received no specific grant from any other funding agency in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The study was approved by the Regional Ethics Committee at Lund University, Lund, Sweden, and the National ethics review authority (2015/859 and 2021–05847). All subjects provided written consent for participation in the study.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Elmståhl, S., Ellström, K., Siennicki-Lantz, A. et al. Incidence of cerebral small vessel disease-related MR markers in the Swedish general population ‘Good Aging in Skåne’(GÅS) study. J Neurol 271, 5997–6003 (2024). https://doi.org/10.1007/s00415-024-12562-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-024-12562-3